Latest & greatest articles for alzheimer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on alzheimer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on alzheimer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Alzheimer’s disease

Alzheimer’s disease is a chronic neurodegenerative disease responsible for the majority of cases of dementia. This progressive disease disrupts memory and thinking due to an accumulation of plaques and tangles in the brain. As the disease progresses, these get progressively worse.

What causes Alzheimer’s diseases is poorly understood, although there is a strong genetic component which could account for the majority (~70%) of the risk. Other risk factors have been identified, such as depression, head injuries and hypertension. Alzheimer’s disease is typically a disease of older people.

Although Alzheimer’s disease cannot currently be cured but it can be managed. With cholinesterase inhibitors being a common intervention as well as memantine (an NMDA receptor antagonist) and psychosocial interventions.

Trip has an extensive collection of research evidence and articles relating to Alzheimer’s disease including clinical guidelines, systematic reviews, synopses, clinical trials and case reports.

Top results for alzheimer

181. Pharmaceutical and non-pharmaceutical interventions for Alzheimer's Disease, a rapid assessment

Pharmaceutical and non-pharmaceutical interventions for Alzheimer's Disease, a rapid assessment Pharmaceutical and non-pharmaceutical interventions for Alzheimer's Disease, a rapid assessment Pharmaceutical and non-pharmaceutical interventions for Alzheimer's Disease, a rapid assessment Hulstaert F, Thiry N, Eyssen M, Vrijens F Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has (...) been made for the HTA database. Citation Hulstaert F, Thiry N, Eyssen M, Vrijens F. Pharmaceutical and non-pharmaceutical interventions for Alzheimer's Disease, a rapid assessment. Brussels: Belgian Health Care Knowledge Centre (KCE). KCE Reports 111C. 2009 Authors' conclusions From the reviews of the literature and the economic evaluations examined here, it appears that the cost-effectiveness studies on the use of donepezil in AD patients have reported a variety of conclusions with studies

Health Technology Assessment (HTA) Database.2009

182. Ginseng for cognitive function in Alzheimer's disease: a systematic review

Ginseng for cognitive function in Alzheimer's disease: a systematic review Ginseng for cognitive function in Alzheimer's disease: a systematic review Ginseng for cognitive function in Alzheimer's disease: a systematic review Lee MS, Yang EJ, Kim JI, Ernst E CRD summary The authors concluded that there was insufficient evidence that ginseng ( Panax ginseng herb) was an effective treatment for Alzheimer's disease, and that further research is needed. Given the small number and low quality (...) of available trials, the authors' cautious conclusions appear to be reliable. Authors' objectives To assess the effectiveness of ginseng ( Panax ginseng herb) on the cognitive function of patients with Alzheimer's disease. Searching The following databases were searched, up to January 2009, for articles in any language: MEDLINE, EMBASE, AMED, CINAHL, PsycINFO, the Cochrane Library, six Korean Medical databases, four Chinese Medical databases, and Japan Science and Technology Information Aggregator. Search

DARE.2009

183. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine

Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine (...) Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine Rodda J, Morgan S, Walker Z CRD summary This review concluded that the evidence base regarding the efficacy of cholinesterase inhibitors for the behavioural and psychological symptoms of dementia was limited. The cautious conclusions reflected the evidence, but should

DARE.2009

184. Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer's disease in Korea

Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer's disease in Korea Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer's disease in Korea Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer's disease in Korea Suh GH Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to determine the cost-effectiveness of including galantamine in the treatment of mild-to-moderately severe Alzheimer’s disease, compared with usual care. The authors concluded that usual care plus galantamine was cost-effective compared with usual care alone. The methods were appropriate and both the methods and results were reported adequately

NHS Economic Evaluation Database.2009

185. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease

Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease Lopez-Bastida J, Hart W, Garcia-Perez L, Linertova R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of treatment with donepezil for patients with mild or moderate Alzheimer's disease compared with no drug treatment. The authors concluded that donepezil was cost-effective for patients with mild Alzheimer's disease in Spain. The methods and reporting of the study were adequate and the authors’ conclusions appear

NHS Economic Evaluation Database.2009

186. Review: rivastigmine reduces rate of cognitive decline and improves performance in mild to moderate Alzheimer?s

Review: rivastigmine reduces rate of cognitive decline and improves performance in mild to moderate Alzheimer?s Review: rivastigmine reduces rate of cognitive decline and improves performance in mild to moderate Alzheimer’s | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: rivastigmine reduces rate of cognitive decline and improves performance in mild to moderate Alzheimer’s Article Text Therapeutics Review: rivastigmine reduces rate of cognitive decline and improves performance in mild to moderate Alzheimer’s Statistics from

Evidence-Based Mental Health2009

187. Cognitive decline fastest in people with Alzheimer?s disease compared with other dementias

Cognitive decline fastest in people with Alzheimer?s disease compared with other dementias Cognitive decline fastest in people with Alzheimer’s disease compared with other dementias | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Cognitive decline fastest in people with Alzheimer’s disease compared with other dementias Article Text Prognosis Cognitive decline fastest in people with Alzheimer’s disease compared with other dementias Statistics from Altmetric.com No Altmetric data available for this article. Question Question: Are there differences

Evidence-Based Mental Health2009

188. High dose vitamin B supplementation does not slow cognitive decline in mild to moderate Alzheimer?s disease

High dose vitamin B supplementation does not slow cognitive decline in mild to moderate Alzheimer?s disease High dose vitamin B supplementation does not slow cognitive decline in mild to moderate Alzheimer’s disease | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here High dose vitamin B supplementation does not slow cognitive decline in mild to moderate Alzheimer’s disease Article Text Therapeutics High dose vitamin B supplementation does not slow cognitive decline in mild to moderate Alzheimer’s disease Statistics from Altmetric.com No Altmetric

Evidence-Based Mental Health2009

189. Continued use of antipsychotic drugs increased long-term mortality in patients with Alzheimer disease

Continued use of antipsychotic drugs increased long-term mortality in patients with Alzheimer disease Continued use of antipsychotic drugs increased long-term mortality in patients with Alzheimer diseaseCommentary | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Continued use of antipsychotic drugs increased long-term mortality in patients with Alzheimer diseaseCommentary Article Text Therapeutics Continued use of antipsychotic drugs increased long-term mortality in patients with Alzheimer disease Commentary Statistics from Altmetric.com No Altmetric data

Evidence-Based Medicine (Requires free registration)2009

190. CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies

CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies Mitchell AJ CRD summary The review found cerebrospinal fluid phosphorylated tau (...) protein was a good marker of probable Alzheimer's disease, a satisfactory marker of mild cognitive impairment and its progression, but less useful for distinguishing Alzheimer’s disease from other dementias. Overall, given weaknesses in the review methods, analysis and the design of the studies, these conclusions appear optimistic and should be viewed with caution. Authors' objectives To assess the accuracy and clinical utility of cerebrospinal fluid phosphorylated tau protein for the diagnosis

DARE.2009

191. To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease

To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease Diniz BS, Pinto JA (...) , Gonzaga ML, Guimaraes FM, Gattaz WF, Forlenza OV CRD summary The authors concluded that long-term use of cholinesterase inhibitors may attenuate the risk of progression from mild cognitive impairment to Alzheimer’s disease/dementia. There were limitations in reporting of review methods but, overall, the authors' conclusions are likely to be reliable. Authors' objectives To determine if cholinesterase inhibitors are effective in delaying the progression from mild cognitive impairment to Alzheimer’s

DARE.2009

192. Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis

Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis Wang BS, Wang H, Wei ZH, Song YY, Zhang L, Chen HZ CRD summary This review (...) assessed the safety and efficacy of huperzine A in Alzheimer's disease. The authors concluded that huperzine A was a well-tolerated drug that could significantly improve cognitive performance and activities in daily living scale in patients with Alzheimer's disease. However, as the results of the pooled analysis may not be reliable, these conclusions should be viewed with caution. Authors' objectives To assess the safety and efficacy of the natural acetyl cholinesterase inhibitor huperzine

DARE.2009

193. Acupuncture for Alzheimer's disease: a systematic review

Acupuncture for Alzheimer's disease: a systematic review Acupuncture for Alzheimer's disease: a systematic review Acupuncture for Alzheimer's disease: a systematic review Lee MS, Shin BC, Ernst E CRD summary This review found that cognitive function and activities of daily living did not improve with acupuncture as a treatment for Alzheimer’s disease, but the number of trials and sample sizes were too small to draw firm conclusions. Given this issue and some concerns with methodology (...) , the authors' conclusions should be treated with some caution. Authors' objectives To assess the evidence for or against the effectiveness of acupuncture as a treatment for Alzheimer's disease. Searching The authors searched the following databases, from inception to August 2008, without language restrictions: MEDLINE, AMED, British Nursing Index, CINAHL, EMBASE, PsycINFO, the Cochrane Library 2008, six Korean medical databases, four Chinese medical databases and three Japanese medical databases. Search

DARE.2009

194. Atypical antipsychotics fail to improve functioning or quality of life in people with Alzheimer?s disease

Atypical antipsychotics fail to improve functioning or quality of life in people with Alzheimer?s disease Atypical antipsychotics fail to improve functioning or quality of life in people with Alzheimer’s disease | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Atypical antipsychotics fail to improve functioning or quality of life in people with Alzheimer’s disease Article Text Therapeutics Atypical antipsychotics fail to improve functioning or quality of life in people with Alzheimer’s disease Statistics from Altmetric.com No Altmetric data available

Evidence-Based Mental Health2009

195. Dimebon improves cognitive function in people with mild to moderate Alzheimer?s disease

Dimebon improves cognitive function in people with mild to moderate Alzheimer?s disease Dimebon improves cognitive function in people with mild to moderate Alzheimer’s disease | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Dimebon improves cognitive function in people with mild to moderate Alzheimer’s disease Article Text Therapeutics Dimebon improves cognitive function in people with mild to moderate Alzheimer’s disease Statistics from Altmetric.com No Altmetric data available for this article. QUESTION Question: Does dimebon improve

Evidence-Based Mental Health2009

196. High-dose vitamin B supplements did not slow cognitive decline in patients with mild-to-moderate Alzheimer disease

High-dose vitamin B supplements did not slow cognitive decline in patients with mild-to-moderate Alzheimer disease High-dose vitamin B supplements did not slow cognitive decline in patients with mild-to-moderate Alzheimer disease | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here High-dose vitamin B supplements did not slow cognitive decline in patients with mild-to-moderate Alzheimer disease Article Text Treatment High-dose vitamin B supplements did not slow cognitive decline in patients with mild

Evidence-Based Nursing (Requires free registration)2009

197. Ginkgo biloba did not prevent dementia or Alzheimer disease in elderly people

Ginkgo biloba did not prevent dementia or Alzheimer disease in elderly people Ginkgo biloba did not prevent dementia or Alzheimer disease in elderly people | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword (...) Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Ginkgo biloba did not prevent dementia or Alzheimer disease in elderly people Article Text Treatment Ginkgo biloba did not prevent dementia or Alzheimer disease in elderly people Free Statistics from Altmetric.com No Altmetric data available for this article. S T DeKosky Dr S T DeKosky, University

Evidence-Based Nursing (Requires free registration)2009

198. Disclosure of APOE genotype for risk of Alzheimer's disease.

Disclosure of APOE genotype for risk of Alzheimer's disease. 19605829 2009 07 16 2009 07 30 2016 12 15 1533-4406 361 3 2009 Jul 16 The New England journal of medicine N. Engl. J. Med. Disclosure of APOE genotype for risk of Alzheimer's disease. 245-54 10.1056/NEJMoa0809578 The apolipoprotein E (APOE) genotype provides information on the risk of Alzheimer's disease, but the genotyping of patients and their family members has been discouraged. We examined the effect of genotype disclosure (...) in a prospective, randomized, controlled trial. We randomly assigned 162 asymptomatic adults who had a parent with Alzheimer's disease to receive the results of their own APOE genotyping (disclosure group) or not to receive such results (nondisclosure group). We measured symptoms of anxiety, depression, and test-related distress 6 weeks, 6 months, and 1 year after disclosure or nondisclosure. There were no significant differences between the two groups in changes in time-averaged measures of anxiety (4.5

NEJM2009 Full Text: Link to full Text with Trip Pro

199. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. 20009055 2009 12 16 2010 01 05 2017 02 20 1538-3598 302 23 2009 Dec 16 JAMA JAMA Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. 2557-64 10.1001/jama.2009.1866 Amyloid-beta peptide (Abeta(42)) has been implicated in the pathogenesis of Alzheimer disease (...) inhibitors or memantine was permitted. Tarenflurbil, 800 mg, or placebo, administered twice a day. Co-primary efficacy end points were the change from baseline to month 18 in total score on the subscale of the Alzheimer Disease Assessment Scale-Cognitive Subscale (ADAS-Cog, 80-point version) and Alzheimer Disease Cooperative Studies-activities of daily living (ADCS-ADL) scale. Additional prespecified slope analyses explored the possibility of disease modification. Of the 1684 participants randomized

JAMA2009 Full Text: Link to full Text with Trip Pro

200. Memantine in Alzheimer's disease

Memantine in Alzheimer's disease Executive Summary IQWiG Reports – Commission No. A05-19C Memantine in Alzheimer’s disease 1 1 Translation of the executive summary of the final report “Memantin bei Alzheimer Demenz” (Version 1.0; Status: 08.07.2009). Please note that this translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Executive summary of final report A05-19C Memantine (...) in Alzheimer’s disease Version 1.0 08.07.2009 Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Memantine in Alzheimer’s disease Contracting agency: Federal Joint Committee Commission awarded on: 22.2.2005 Internal Commission No.: A05-19C Publisher’s address: Institute for Quality and Efficiency in Health Care Dillenburger Str. 27 51105 Cologne Germany Tel.: +49 221 35685-0 Fax: +49 221 35685-1 berichte@iqwig.de www.iqwig.de Institute for Quality and Efficiency

Institute for Quality and Efficiency in Healthcare (IQWiG)2009